Entospletinib

Entospletinib

Clinical data
Other names	GS-9973
Legal status
Legal status	Investigational
Identifiers
IUPAC name 6-(1H-Indazol-6-yl)-N-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyrazin-8-amine
CAS Number	1229208-44-9
PubChem CID	59473233
DrugBank	12121
UNII	6I3O3W6O3B
KEGG	D11209
CompTox Dashboard (EPA)	DTXSID001317670
Chemical and physical data
Formula	C23H21N7O
Molar mass	411.469 g·mol−1
3D model (JSmol)	Interactive image
SMILES c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1
InChI InChI=1S/C23H21N7O/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29/h1-8,13-15H,9-12H2,(H,25,28)(H,26,27) Key:XSMSNFMDVXXHGJ-UHFFFAOYSA-N

Entospletinib is an experimental drug for the treatment of various types of cancer under development by Gilead Sciences. It is an inhibitor of spleen tyrosine kinase (Syk).^[1] It has entered clinical trials for acute myeloid leukaemia (AML), chronic lymphocytic leukemia (CLL),^[2] diffuse large B cell lymphoma (DLBCL), graft-versus-host disease (GvHD), hematological malignancies, mantle cell lymphoma (MCL), and non-Hodgkin lymphoma (NHL).^[3]

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

• v
• t
• e